JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 4
DOI:10.33266/1024-6177-2025-70-4-102-105
E.V. Efanova1, 2, Zh.A. Startseva3, S.A. Fursov1, 2, A.L. Chernyshova1, 4,
O.A. Tkachuk1, 2
Features of Radiation Reactions in Patients with Prostate Cancer
with Metabolic Syndrome on the Background of Thermoradiotherapy
1 Novosibirsk State Medical University, Novosibirsk, Russia
2 Novosibirsk Regional Clinical Oncological Dispensary, Novosibirsk, Russia
3 Cancer Research Institute of Tomsk National Research Medical Center, Tomsk. Russia
4 E.N. Meshalkin National Medical Research Center, Novosibirsk, Russia
Contact person: Ekaterina V. Efanova, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ANNOTATION
Background: Prostate cancer (PC) is one of the most common cancers in men. According to the statistics of the Russian Federation for 2023, prostate cancer ranks 1st among malignant neoplasms in men (19.1 %) and 3rd (8.3 %) in the structure of mortality from malignant neoplasms in the male population. One of the main methods of treating prostate cancer is remote radiation therapy, with a combination of radiotherapy and local hyperthermia, the term thermoradotherapy is used. There has been a steady increase in patients with metabolic syndrome (MS) among prostate cancer patients. Given the complex hormonal and metabolic changes in MS, it is currently believed that this syndrome is a potential risk factor for an unfavorable prognosis in the treatment of prostate cancer.
Purpose: to evaluate the effect of metabolic syndrome in patients with prostate malignancy on the frequency and severity of adverse events during thermoradotherapy.
Material and methods: This non-randomized comparative study involved 60 patients diagnosed with prostate cancer (adenocarcinoma) T3-T4N0M0 who received remote radiation therapy using volume modulated therapy (VMAT) with irradiation of the prostate gland, seminal vesicles, and pelvic lymph nodes to a total focal dose (SOD) of 80/80/50 Gy in the mode 5 times a week, 28 sessions, on Electa linear electron accelerators Versa HD (Great Britain), photon beam of 6 Mev energy with local hyperthermia radio modification on a Celsius TCS device (Germany) according to the scheme: 2 times a week, 8–10 procedures in total 2 hours before radiation therapy, heating duration 40–60 minutes at a temperature of 40–42 °C. The study group included 30 people who received thermoradotherapy and were diagnosed with metabolic syndrome (according to the criteria of the IDF in 2009) before starting treatment. The control group consisted of 30 patients undergoing thermoradotherapy without a history of metabolic syndrome.
Results and discussion: Analysis of these patient groups shows that in the category of prostate cancer patients with metabolic syndrome, compared with the control group, more pronounced radiation reactions prevail, such as radioepitheliitis on the skin at the site of irradiation and nocturia. Metabolic changes cause disorders of lymphatic and circulatory microcirculation, skin repair processes; abdominal obesity leads to increased intra-abdominal pressure, which increases the frequency of urination at night.
Conclusion: Prostate cancer patients with metabolic syndrome receiving thermoradotherapy require great attention from doctors due to the increased risk of developing severe radiation reactions. In this regard, further research in this area is necessary, which makes an unconditional contribution to improving the effectiveness of treatment in this category of patients.
Keywords: prostate cancer, radiation therapy, local hyperthermia, thermoradotherapy, metabolic syndrome, radiation reactions
For citation: Efanova EV, Startseva ZhA, Fursov SA, Chernyshova AL, Tkachuk OA. Features of Radiation Reactions in Patients with Prostate Cancer with Metabolic Syndrome on the Background of Thermoradiotherapy. Medical Radiology and Radiation Safety. 2025;70(4):102–105. (In Russian). DOI:10.33266/1024-6177-2025-70-4-102-105
References
1. Kaprin A.D., Starinskiy V.V., Petrova G.V. Zlokachestvennyye Novoobrazovaniya v Rossii v 2023 Godu (Zabolevayemost’ i Smertnost’) = Malignant Neoplasms in Russia in 2023 (Morbidity and Mortality). Moscow, Moskovskiy Nauchno-Issledovatel’skiy Onkologicheskiy Institut Imeni P.A.Gertsena Publ., 2023. 276 p. (In Russ.).
2. Kipriyanov Ye.A. Gipertermiya kak Komponent Kompleksnogo Lecheniya Bol’nykh Rakom Predstatel’noy Zhelezy = Hyperthermia as a Component of Complex Treatment of Patients with Prostate Cancer. Doctor’s Thesis (Med.). Moscow Publ., 2009. 154 p. (In Russ.).
3. Nosov D.A., Volkova M.I., Gladkov O.A., Karabina Ye.V., Krylov V.V., Matveyev V.B., et al. Practical Recommendations for drug Treatment of Prostate Cancer. Prakticheskiye Rekomendatsii RUSSCO = Practical Recommendations RUSSCO. 2023;13:640-660 (In Russ.). doi: 10.18027/2224-5057-2021-11-3s2-33 (In Russ.).
4. Peshkov M.N., Peshkova G.P., Reshetov I.V. Metabolic Changes in Patients with Prostate Cancer during Androgen Deprivation Therapy. Sakharnyy Diabet = Diabetes Mellitus. 2020;23;2:192-200 (In Russ.).
5. Moon S., Chung H.S., Yu J.M., Ko K.J., Choi D.K., Kwon O., Lee Y.G., Cho S.T. The Association Between Obesity and the Nocturia in the U.S. Population. Int Neurourol J. 2019 Jun;23;2:169-176.
6. Knights A.J., Funnell A.P., Pearson R.C., et al. Adipokines and Insulin Action: a Sensitive Issue. Adipocyte. 2014;3;2:88-96.
7. Losano G., Folino A., Rastaldo R. Role of Three Adipokines in Metabolic Syndrome. Pol Arch Med Wewn. 2016;126;4:219-221.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. E.V. Efanova – study design, patient selection according to inclusion criteria, patient management, filling out primary documentation, writing the manuscript; Z.A. Startseva – general management of the study, proofreading the article; S.A. Fursov – general management of the study, proofreading the article; A.L. Chernyshova –proofreading the article; O.A. Tkachuk – study design, proofreading the article. All authors read and approved the final version before publication.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.03.2025. Accepted for publication: 25.04.2025.